News | March 11, 2025
Syngene acquires first US biologics facility for $36.5 million
Overall investment in the US facility is estimated around US$50 million
Overall investment in the US facility is estimated around US$50 million
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The observations issued are neither repeated observations nor related to data integrity
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Subscribe To Our Newsletter & Stay Updated
